evidence table

Chicory Root Gut Microbiota Randomized Trial Evidence Table

Structured evidence table for Chicory Root Gut Microbiota Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
Chicory Root Gut Microbiota Randomized TrialIt is postulated that, apart from genetic predisposition, the rise of local and systemic immune response in PS could be a consequence of intestinal dysbiosis associated with increased intestinal permeability.2Krupa-Kozak U (2026)INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
Chicory Root Gut Microbiota Randomized TrialWe expect that the RCT results will enable the introduction of personalised dietary therapy with prebiotic ITFs, which, unlike other PS therapies, would not pose a high risk of side effects.2Krupa-Kozak U (2026)INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
Chicory Root Gut Microbiota Randomized TrialBACKGROUND: A strong, bidirectional association exists between gastrointestinal health and skin homeostasis in many chronic skin inflammations, including psoriasis (PS).2Krupa-Kozak U (2026)INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
Chicory Root Gut Microbiota Randomized TrialClinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo.4Kerezoudi EN (2026)Dietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.
Chicory Root Gut Microbiota Randomized TrialIn an intestinal barrier challenge model, chRG-I fermentates (a pool of metabolites including SCFA and fragments of chRG-I) protected barrier integrity, modulated the cytokine milieu away from a predominantly pro-inflammatory response, as characterized by increased IL4 and IL22 and reduced IL9, IL17A, and IL21.4Kerezoudi EN (2026)Dietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.
Chicory Root Gut Microbiota Randomized TrialConclusion: Supplementation with a low dose of chRG-I is well-tolerated, beneficially modulates the gut microbiome - which can protect the intestinal barrier, and subtly enhances systemic immune readiness, suggesting that chRG-I may have benefits as a functional food ingredient.4Kerezoudi EN (2026)Dietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.
Chicory Root Gut Microbiota Randomized TrialBackground: Pectic rhamnogalacturonan-I (RG-I) is a dietary fiber that modulates the gut-immune axis.4Kerezoudi EN (2026)Dietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.
topicChicory Root Gut Microbiota Randomized Trial
claimIt is postulated that, apart from genetic predisposition, the rise of local and systemic immune response in PS could be a consequence of intestinal dysbiosis associated with increased intestinal permeability.
evidence level2
citationKrupa-Kozak U (2026)
sourceINulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
topicChicory Root Gut Microbiota Randomized Trial
claimWe expect that the RCT results will enable the introduction of personalised dietary therapy with prebiotic ITFs, which, unlike other PS therapies, would not pose a high risk of side effects.
evidence level2
citationKrupa-Kozak U (2026)
sourceINulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
topicChicory Root Gut Microbiota Randomized Trial
claimBACKGROUND: A strong, bidirectional association exists between gastrointestinal health and skin homeostasis in many chronic skin inflammations, including psoriasis (PS).
evidence level2
citationKrupa-Kozak U (2026)
sourceINulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
topicChicory Root Gut Microbiota Randomized Trial
claimClinically, chRG-I was well-tolerated and slightly improved stool consistency compared to placebo.
evidence level4
citationKerezoudi EN (2026)
sourceDietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.
topicChicory Root Gut Microbiota Randomized Trial
claimIn an intestinal barrier challenge model, chRG-I fermentates (a pool of metabolites including SCFA and fragments of chRG-I) protected barrier integrity, modulated the cytokine milieu away from a predominantly pro-inflammatory response, as characterized by increased IL4 and IL22 and reduced IL9, IL17A, and IL21.
evidence level4
citationKerezoudi EN (2026)
sourceDietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.
topicChicory Root Gut Microbiota Randomized Trial
claimConclusion: Supplementation with a low dose of chRG-I is well-tolerated, beneficially modulates the gut microbiome - which can protect the intestinal barrier, and subtly enhances systemic immune readiness, suggesting that chRG-I may have benefits as a functional food ingredient.
evidence level4
citationKerezoudi EN (2026)
sourceDietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.
topicChicory Root Gut Microbiota Randomized Trial
claimBackground: Pectic rhamnogalacturonan-I (RG-I) is a dietary fiber that modulates the gut-immune axis.
evidence level4
citationKerezoudi EN (2026)
sourceDietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.

Learn next

Related evidence and supplement guides

SupplementAkkermansia MuciniphilaA next-generation gut bacterium that plays a crucial role in strengthening the intestinal mucin...SupplementProbioticsLive beneficial bacteria that support digestive health, immune function, and the gut-brain axis.GuideChicory Root Gut Microbiota Randomized Trial: What the Evidence SaysChicory Root Gut Microbiota Randomized Trial has 2 source documents in the current Migaku eviden...GuideChicory Root Constipation Randomized Trial: What the Evidence SaysChicory Root Constipation Randomized Trial has 2 source documents in the current Migaku evidence...GuideChicory Root Blood Glucose Randomized Trial: What the Evidence SaysChicory Root Blood Glucose Randomized Trial has 2 source documents in the current Migaku evidenc...GuideChicory Root Fiber Satiety Randomized Trial: What the Evidence SaysChicory Root Fiber Satiety Randomized Trial has 2 source documents in the current Migaku evidenc...RankingBest Probiotics for Gut Health: 2026 Evidence Review & RankingsWe analyzed over 25 probiotic brands to find the best formulations containing scientifically val...RankingBest Gut Health Supplements 2026: Ranked by EvidenceThe gut health supplement market is full of overclaimed products. These have the strongest evide...

Source documents

  1. INulin-type β-fructans supplementation to modulate gut microbiota and assessment of its effects on health status and GUT-SKIN axis parameters in patients with psoriasis (INGUTSKIN): the 8-week, randomised, double-blind, placebo-controlled clinical study protocol.
  2. Dietary chicory rhamnogalacturonan-I modulates gut microbiota and immune responses in healthy adults.